Ascendis Pharma A/S
ASND
Classifica tra le azioni
#1508
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Prezzo delle azioni
$230.45
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$14.37B
Variazione (1 giorno)
2.31%
Variazione (1 anno)
12.30%
Paese
DK
Scambia Ascendis Pharma A/S (ASND)
Categoria
Healthcare
Utile per Ascendis Pharma A/S (ASND)
Utile nel Jun 2026 TTM: $119.93M
Secondo gli ultimi rapporti finanziari di Ascendis Pharma A/S, gli utili attuali della società sono $119.93M. Nel 2024, la società ha registrato un utile di $-388.38M, un aumento rispetto a agli utili del 2023, che erano di $-524.15M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Ascendis Pharma A/S dal 2012 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $119.93M | -150.04% |
| 2025 | $-239.65M | -38.30% |
| 2024 | $-388.38M | -25.90% |
| 2023 | $-524.15M | -15.43% |
| 2022 | $-619.81M | 41.96% |
| 2021 | $-436.60M | -14.48% |
| 2020 | $-510.50M | 108.47% |
| 2019 | $-244.87M | 63.30% |
| 2018 | $-149.95M | 0.48% |
| 2017 | $-149.24M | 106.36% |
| 2016 | $-72.32M | 98.38% |
| 2015 | $-36.46M | 191.39% |
| 2014 | $-12.51M | -293.36% |
| 2013 | $6.47M | 281.71% |
| 2012 | $1.70M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $5.27B | 4,298.37% |
US
|
|
| $-3.09B | -2,674.04% |
US
|
|
| $-4.02B | -3,448.83% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,526.51% |
NL
|
